▲ +18.92% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for RadNet in the last 3 months. The average price target is $22.50, with a high forecast of $23.00 and a low forecast of $22.00. The average price target represents a 18.92% upside from the last price of $18.92.
The current consensus among 2 polled investment analysts is to buy stock in RadNet. This Buy consensus rating has held steady for over two years.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of hospitals and hospital-based radiology groups. As of December 31, 2019, it operated 335 centers in California, Delaware, Florida, Maryland, New Jersey, and New York. RadNet, Inc. has a collaboration with Hologic, Inc. to advance the use of artificial intelligence in breast health. The company was founded in 1985 and is headquartered in Los Angeles, California.